As Idit pointed out sometime near the end of March. One thing to keep in mind is that viral relapse was found four weeks into the follow-up period in nulls so stunning 12-week SVR data doesn't necessarily mean the results will continue to hold during follow-up.
I'm inclined to agree because I think the goal is to ultimately remove riba as well.
From a patient tolerability standpoint this may be true. Ideally GILD would prefer to dominate the space for treatment-naive patients using the generic ribavirin combination.
Market Data 
Markets 
AI
